• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by SNDL Inc.

    8/20/25 10:05:34 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SNDL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    SNDL Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    68404V209

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    68404V209


    1Names of Reporting Persons

    Armistice Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    754,867.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    754,867.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    754,867.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.29 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    68404V209


    1Names of Reporting Persons

    Steven Boyd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    754,867.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    754,867.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    754,867.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.29 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    SNDL Inc.
    (b)Address of issuer's principal executive offices:

    919 11 AVENUE SW, SUITE 300, CALGARY AB T2R 1P3
    Item 2. 
    (a)Name of person filing:

    Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
    (b)Address or principal business office or, if none, residence:

    Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
    (c)Citizenship:

    Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    68404V209
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    754,867
    (b)Percent of class:

    0.29  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    754,867

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    754,867 The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer. Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Armistice Capital, LLC
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd - Managing Member
    Date:08/20/2025
     
    Steven Boyd
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd
    Date:08/20/2025
    Exhibit Information

    JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 20, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

    Get the next $SNDL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNDL

    DatePrice TargetRatingAnalyst
    7/17/2024Speculative Buy
    Canaccord Genuity
    8/16/2022$5.00Hold → Speculative Buy
    Canaccord Genuity
    5/3/2022$0.60 → $0.70Underperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $SNDL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SNDL Inc.

    SCHEDULE 13G/A - SNDL Inc. (0001766600) (Subject)

    8/20/25 10:05:34 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SCHEDULE 13G filed by SNDL Inc.

    SCHEDULE 13G - SNDL Inc. (0001766600) (Subject)

    8/14/25 8:58:36 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    7/31/25 5:01:45 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity resumed coverage on SNDL Inc.

    Canaccord Genuity resumed coverage of SNDL Inc. with a rating of Speculative Buy

    7/17/24 12:19:57 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Sundial Growers upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Sundial Growers from Hold to Speculative Buy and set a new price target of $5.00

    8/16/22 7:59:34 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Sundial Growers upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Sundial Growers from Underperform to Market Perform and set a new price target of $0.70 from $0.60 previously

    5/3/22 7:19:03 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SNDL Announces 2025 Annual and Special Meeting Results

    EDMONTON, AB, July 31, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual and Special Meeting of Shareholders (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at seven (7); (ii) electing each of Gregory Mills, J. Carlo Cannell, Lori Ell, Zachary George, Frank Krasovec, Bryan Pinney, and Gregory Turnbull as directors of the Company for the ensuing year; (iii) re-appointing CBIZ

    7/31/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Reports Second Quarter 2025 Financial and Operational Results

    The Company Delivers Positive Operating Income EDMONTON, AB, July 31, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the second quarter ended June 30, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Thursday, July 31,

    7/31/25 7:00:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL to Announce Second Quarter 2025 Financial Results on July 31, 2025

    EDMONTON, AB, July 10, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL") announced today that it will release its second quarter 2025 financial results for the period ended June 30, 2025, before market opens on Thursday, July 31, 2025. Following the release of its second quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on July 31, 2025. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/3q3tisco ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL

    7/10/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Financials

    Live finance-specific insights

    View All

    SNDL Reports Second Quarter 2025 Financial and Operational Results

    The Company Delivers Positive Operating Income EDMONTON, AB, July 31, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the second quarter ended June 30, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Thursday, July 31,

    7/31/25 7:00:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL to Announce Second Quarter 2025 Financial Results on July 31, 2025

    EDMONTON, AB, July 10, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL") announced today that it will release its second quarter 2025 financial results for the period ended June 30, 2025, before market opens on Thursday, July 31, 2025. Following the release of its second quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on July 31, 2025. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/3q3tisco ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL

    7/10/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Reports First Quarter 2025 Financial and Operational Results

    The Company Delivers Record Gross Margin and Positive Cash Flow; Announces Strategic Review of U.S. Platform and Listing Structure EDMONTON, AB, May 1, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the first quarter ended March 31, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference cal

    5/1/25 7:00:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Leadership Updates

    Live Leadership Updates

    View All

    SNDL Announces 2025 Annual and Special Meeting Results

    EDMONTON, AB, July 31, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual and Special Meeting of Shareholders (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at seven (7); (ii) electing each of Gregory Mills, J. Carlo Cannell, Lori Ell, Zachary George, Frank Krasovec, Bryan Pinney, and Gregory Turnbull as directors of the Company for the ensuing year; (iii) re-appointing CBIZ

    7/31/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Appoints New Chief Information Officer and New President, Liquor Division

    CALGARY, AB, Nov. 21, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the appointments of Phil McBride as Chief Information Officer and Navroop Sandhawalia as President, Liquor Division. "SNDL's success is driven by our commitment to talent density and our leaders are the foundation of our performance culture," said Zach George, Chief Executive Officer of SNDL.  "Phil's extensive expertise in technology and digital innovation, paired with Nav's financial acumen and best-in-class retail experience will further strengthen our executio

    11/21/24 6:02:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Announces 2024 Annual General Meeting Results

    CALGARY, AB, July 30, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual General Meeting (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at six (6); (ii) electing each of Gregory Mills, Zachary George, Lori Ell, Frank Krasovec, Bryan Pinney and Gregory Turnbull as directors of the Company for the ensuing year; and (iii) re-appointing Marcum LLP as the auditors of the Company for the ensu

    7/30/24 5:45:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    1/31/24 4:48:48 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Subject)

    2/14/23 5:28:02 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    2/13/23 4:06:09 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care